Hardi Patel
Primary Care · Dover, DENPI 1558972398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $987, 5.1 times the $195 reported in 2021.
Across 145 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$529
- AstraZeneca$328
- Lilly USA, LLC$224
- Astellas Pharma US Inc$140
- Dexcom, Inc.$127
- Pfizer$115
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,621100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $529 |
| AstraZeneca | 16 | $328 |
| Lilly USA, LLC | 11 | $224 |
| Astellas Pharma US Inc | 9 | $140 |
| Dexcom, Inc. | 7 | $127 |
| Pfizer | 5 | $115 |
| Exact Sciences | 4 | $93 |
| Xeris Pharmaceuticals, Inc. | 5 | $81 |
| Abbott | 4 | $79 |
| AbbVie | 3 | $78 |
| Amgen | 5 | $76 |
| Boehringer Ingelheim | 5 | $74 |
| GSK | 4 | $69 |
| Bayer | 4 | $67 |
| Sanofi-aventis U.S. LLC | 3 | $62 |
| Phathom Pharmaceuticals, Inc. | 4 | $59 |
| Novartis | 4 | $58 |
| Viiv Healthcare Company | 2 | $50 |
| Medtronic | 2 | $50 |
| Shield Therapeutics Inc | 2 | $46 |
| Merck | 3 | $40 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Microtransponder, Inc. | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Verona Pharma, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Watermark Medical, Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
How this compares
$2,621 in reported general payments places this provider in the 85th percentile of 25 primary care providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 33 | $54,012 |
| FarxigaDapagliflozin Propanediol | 25 | $25,026 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $18,259 |
| EliquisApixaban | 15 | $17,929 |
| OzempicSemaglutide | 12 | $15,153 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,751 |
| Tizanidine Hcl | 33 | $4,327 |
| Fluticasone Propionate | 99 | $1,891 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,694 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,619 |
| Azelastine Hcl | 63 | $1,532 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,521 |
| Atorvastatin Calcium | 139 | $1,404 |
| Levothyroxine Sodium | 51 | $982 |
| Gabapentin | 64 | $849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $74 | $54,01233 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $69 | $26,01028 claims |
| AstraZenecaFarxiga | $328 | $25,02625 claims |
| PfizerEliquis | $115 | $17,92915 claims |
| Novo NordiskOzempic | $529 | $15,15312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 25 primary care providers in Delaware.
Other primary care in Dover
- Hannah HierlmaierDover$1K
- Florence AkouegnonWilmington$5K
- Catherine SlaughWilmington$4K
- Cynthia Lang-GroeningWilmington$3K
- Rachael OfiliNewark$2K
- Julie MbuaWilmington$1K
- Lisa StaabGeorgetown$1K
- Hanh NguyenBear$1K
- Christina RiceWilmington$618
- Teresa CohanRehoboth Beach$506
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.